MiRagen Therapeutics (Viridian Therapeutics)

Founded in 2007 and based in Colorado, US, Viridian Therapeutics, Inc. formerly known as MiRagen Therapeutics, Inc. operates as a biotechnology company that develops cardiovascular and muscle disease therapeutics based on microRNA biology. In January 2024, Viridian Therapeutics, Inc.14 million shares at USD 21 per share on the Nasdaq Global Select Market under the ticker symbol VRDN. Viridian Therapeutics develops therapies for patients with autoimmune and rare diseases. The company's portfolio includes a pipeline of investigational therapeutic candidates. Central to their efforts is a focus on thyroid eye disease (TED), exemplified by their candidate, VRDN-001, currently in pivotal Phase 3 trials (THRIVE and THRIVE-2). These studies aim to evaluate the drug's efficacy and safety for patients with active and chronic TED. Additionally, VRDN-003, another candidate, offers a promising subcutaneous therapy option, with plans underway for its own Phase 3 program (REVEAL-1 and REVEAL-2). Other pipeline products include VRDN-006 and VRDN-008, which hold potential across multiple autoimmune diseases.

1. Series C

   Nov 10, 2015

   Amount

   $41M

   Investors

   Locked

2. Series B

   Feb 17, 2015

   Amount

   $8.5M

   Investors

   Locked

3. Series B

   Jun 27, 2014

   Amount

   $7M

   Investors

   Locked

4. Series B

   Apr 10, 2012

   Amount

   $6M

   Investors

   Locked

5. Series B

   Jun 3, 2009

   Amount

   $4M

   Investors

   Locked

6. Series A

   May 19, 2008

   Amount

   $8M

   Investors

   Locked